{
    "organizations": [],
    "uuid": "fe312136b6568481755e4263d80614742318b01b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-vitrolife-buys-licensing-rights-fo/brief-vitrolife-buys-licensing-rights-for-embryo-transfer-technology-idUSASM000I0L",
    "ord_in_thread": 0,
    "title": "BRIEF-Vitrolife buys licensing rights for embryo transfer technology",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 11 (Reuters) - Vitrolife AB:\n* VITROLIFE ACQUIRES LICENSING RIGHTS TO TECHNOLOGY FOR EMBRYO TRANSFER\n* SAYS ‍INTENDS TO COMMERCIALISE TECHNOLOGY BY MARKETING A UNIQUE EMBRYO TRANSFER CATHETER​\n* SAYS ‍INITIAL PURCHASE PRICE AMOUNTED TO USD 5 MILLION​ * SAYS ‍ACQUISITION IS EXPECTED TO IMPACT EBITDA PER SHARE MARGINALLY NEGATIVELY DURING 2018-2020 AND POSITIVELY AS FROM 2021​ Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-01-11T15:35:00.000+02:00",
    "crawled": "2018-01-12T18:37:38.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "vitrolife",
        "ab",
        "vitrolife",
        "acquires",
        "licensing",
        "right",
        "technology",
        "embryo",
        "transfer",
        "say",
        "commercialise",
        "technology",
        "marketing",
        "unique",
        "embryo",
        "transfer",
        "say",
        "purchase",
        "price",
        "amounted",
        "usd",
        "say",
        "expected",
        "impact",
        "ebitda",
        "per",
        "share",
        "marginally",
        "negatively",
        "positively",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}